available methods for delivery of viruses and virus-sized particles to the CNS, investigations into the feasibility of using CED to distribute these vectors have been performed. 6, 13 Although data from these studies have demonstrated the feasibility of using CED to deliver viruses and virus-sized vectors to the CNS, the convective distribution properties and the parameters for optimal distribution of viruses themselves are unknown. To define and optimize the convective properties in the CNS, we coinfused a similar virus-sized MR imaging agent (ferumoxtran-10; 24-nm diameter) and labeled AAV capsids (24 nm) into rat and primate brain by using CED during real-time MR imaging.
Materials and Methods

Ferumoxtran-10 MR Imaging Agent
We used commercially available ferumoxtran-10 (Combidex, Advanced Magnetics) as a surrogate MR imaging agent. Various concentrations of ferumoxtran-10 (0.1, 0.5, 1, and 5 mg/ml) were created by dissolving the agent in a solution of phosphate-buffered saline to the desired concentration (pH 7.2).
Preparation of 35 S-AAV Capsids
Fifty milliliters of SF9 insect cells at 2 ϫ 10 6 /ml were infected with AAV capsid baculovirus (serotype 1 [AAV-1]) in complete SF900 medium (Invitrogen) at a multiplicity of infection of 5 for 20 hours. Cells were pelleted and conditioned for labeling by adding 50 ml of methionine-and cysteine-depleted medium (Invitrogen) for 2 hours, at which time 25 ml of methionine-and cysteine-depleted medium containing 2.5 mCi of L-[ 35 
S]methionine and L-[
35 S]cysteine (Promix, Amersham) were added to the cell pellets for pulse labeling. After 4 hours, 25 ml of complete medium was added and cells were incubated overnight. Cells were pelleted by centrifugation, resuspended in phosphate-buffered saline, and subjected to three cycles of freezing and thawing. The lysate was clarified by centrifugation and the supernatant containing the labeled AAV capsids was purified through a 1-ml diethylaminoethyl column equilibrated with column buffer (20 mM Bis-Tris, pH 5.9, 10 mM NaCl) and eluted with 150 mM NaCl column buffer. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed on diethylaminoethyl fractions. Following electrophoresis, one set of gels was used for the autoradiographic detection of radiolabeled proteins, confirming that the sulfur-35 is covalently associated with the capsid proteins. Western blot analysis in which anti-AAV rabbit serum was used confirmed that the labeled proteins were from AAV particles. Fractions containing the highest labeling determined by scintillation counting were pooled. Virus titers measured 0.5 to 1.0 ϫ 10 14 viral particles/ml.
Animals Used
Sixteen Sprague-Dawley rats and five adult nonhuman primates (Macaca fascicularis) were used. All procedures were performed in accordance with the regulations of the Animal Care and Use Committee of the National Institute of Neurological Disorders and Stroke and the National Institutes of Health Radiation Safety Committee.
Rodent Study
Cannula Placement and Infusion. Convective coinfusion of 35 S-AAV capsids and ferumoxtran-10 to the rat striatum was performed using techniques described previously. 7 Briefly, animals were anesthetized by intraperitoneal injection of ketamine (80 g/kg) and placed in a stereotactic frame (model 900, Kopf Instruments). A gastight 25-l Hamilton syringe with a blunt 32-gauge stainless-steel needle was stereotactically placed in the right striatum (coordinates: 1.0 mm anterior to bregma, 2.5 mm lateral to bregma, and 4 mm deep to the dura mater).
To determine the optimal concentration of ferumoxtran-10 for tracking distribution of AAV, 4 l of the agent (final concentrations 0.1, 0.5, 1, and 5 mg/ml; four rats at each concentration) combined with 35 S-AAV capsids at titers of 0.5 to 1.0 ϫ 10 14 viral particles/ml were infused at 0.1 l/minute.
Protocol for MR Imaging. Immediately following the infusion, animals underwent T2-weighted MR imaging on a 4.7-tesla MR unit (coronal and axial planes; 1 mm with no spacing, TR ~ 8300 msec, TE ~ 110 msec).
Determination of Vd on MR Imaging. The Vd on MR imaging was calculated using NIH ImageJ software. The area on each slice was determined using a threshold for segmentation as the MR signal intensity value two standard deviations below the mean baseline MR signal of the surrounding noninfused anatomical region. 35 These were then summed to derive the MR imaging Vd of the infusate.
Quantitative Autoradiography. Animals were killed immediately after completion of MR imaging. Their brains were harvested and snap-frozen. Brains were serially sectioned into 20--thick sections, and every fifth section was analyzed for radioactive viral capsid distribution by using a bio-imaging system (BAS-5000, Fuji Medical Systems). The area of radiolabeled capsid distribution on each slide was measured using commercially available software (Image Gauge, version 4.22, Fuji Medical Systems). A threshold for segmentation of 10% of the value obtained from the region of interest containing the maximum optical density was used to determine the area of distribution. The Vd was calculated by summing the areas and multiplying by 0.1 mm. The Vd determined from quantitative autoradiography was compared with the Vd of ferumoxtran-10 on MR imaging.
Primate Infusion of Ferumoxtran-10 and
35
S-AAV Capsids
Infusion Cannula Placement. Infusion cannula placement and convective coinfusion of 35 S-AAV capsids and ferumoxtran-10 to the primate striatum were performed using techniques described previously. 23 The animal was sedated, intubated, and maintained under general endotracheal anesthesia with isoflurane. The animal's temperature, heart rate, oxygen saturation, electrocardiographic responses, and endtidal partial pressure of carbon dioxide were monitored throughout the operation. The head of the animal was secured in a Kopf stereotactic frame (Crist Instrument Co., Inc.). Using sterile technique, a midline skin incision was made from the anterior to the posterior aspect of the vertex of the skull and a self-retaining retractor was used to expose the underlying skull. A 6-mm bur hole was placed over the stereotactically determined entry point, and the underlying dura mater was incised. A 22-gauge outer guide cannula of fused silicate (outer diameter 0.027 in, inner diameter 0.02 in) was stereotactically guided through the dural opening along the target trajectory to a level 1.5 cm above the desired target. The guide cannula was secured in place with methylmethacrylate. The 28-gauge inner cannula (outer diameter 0.014 in, inner diameter 0.006 in; guide and inner cannulas obtained from Plastics One) was then placed through the outer guide cannula to position the tip at the target. After infusion and cannula placement, the animal was transported to the imaging suite for real-time MR imaging during infusion.
Infusion and MR Imaging. A Harvard syringe pump (PHD 2000, Harvard Apparatus, Inc.) was used to generate continuous pressure throughout the infusion procedure. 23 During infusion, the pressure was transmitted from the pump to a plastic disposable 6-ml syringe that was connected to thick-walled PE50 polyethylene tubing (outer diameter 0.050 in, inner diameter 0.023 in; Plastics One). The tubing was connected to the inner infusion cannula with its tip in the striatum.
The infusion was performed starting at a rate of 0.1 l/minute. The rate was increased to 0.25 l/minute and then to a final rate of 0.5 l/minute in 15-minute intervals. During the infusion, serial coronal T2-weighted images were obtained (slice thickness 1 mm with no spacing) on a Phillips 3.0-tesla MR imager.
Determination of Vd on MR Imaging and Quantitative Autoradiography. The Vd on MR imaging and quantitative autoradiography were determined as described previously in the text.
Primate Infusion of Ferumoxtran-10 Alone
Infusion Cannula Placement. Placement of the infusion cannula in the primate striatum was performed as described earlier. After infu-sion cannula placement, the animal was taken to the imaging suite for infusion and real-time MR imaging.
Infusion and MR Imaging. The ferumoxtran-10 infusion was performed starting at a rate of 0.1 l/minute by using the infusion apparatus described earlier. The rate was increased to 0.25 l/minute and then increased by 0.25 or 0.50 every 15 minutes until leakback was seen on MR imaging. Throughout the infusion, serial coronal T2-weighted MR images were obtained (slice thickness 1 mm with no spacing) on a Phillips 3.0-tesla MR unit. Immediately after completion of the infusion, the cannula was removed and the animal was awakened.
Determination of Vd on MR Imaging. The Vd on MR imaging was calculated as previously described in the text.
Clinical Observation. The animals were examined daily for behavioral evidence of toxicity. Primates were killed at 0, 36, 59, and 72 days after infusion (Table 1) .
Histological Evaluation. After planned death, the brains were harvested, frozen, sectioned in 20--thick sections, and stained with H & E and Luxol fast blue. Sections were reviewed by an independent pathologist.
Results
Ferumoxtran-10 as an MR Imaging Tracer
To determine the concentration of ferumoxtran-10 that would most accurately represent the actual Vd and anatomical distribution of AAV capsids, we initially coinfused radiolabeled 35 S-AAV capsids and serial concentrations of ferumoxtran-10 in the rat striatum while monitoring distribution by using T2-weighted MR imaging and performing quantitative autoradiography. The ferumoxtran-10 concentration that most accurately represented the Vd of the AAV capsid on MR imaging was 1 mg/ml ( Fig. 1 ). At this concentration the mean Vd based on MR imaging was 20.5 Ϯ 2 mm 3 compared with the Vd according to quantitative autoradiography, which was 21.9 Ϯ 1.5 mm 3 of ferumoxtran-10 (a difference of 7%). To confirm the accuracy of ferumoxtran-10 as a tracer for AAV in a larger brain, we also coinfused the striatum of one monkey with 1 mg/ml ferumoxtran-10 and 
Real-Time MR Imaging of Ferumoxtran-10
Imaging Protocol. Once the optimal concentration of ferumoxtran-10 as a surrogate for AAV had been determined, to examine the optimal rate of infusion for AAV and to assess the feasibility of distributing virus-sized molecules in the brain over clinically relevant volumes, we performed real-time MR imaging in primates during convective delivery of ferumoxtran-10 to different regions of the brain. The T2-weighted MR imaging performed at intervals during infusions demonstrated that the anatomical region perfused with ferumoxtran-10 was clearly distinguishable from the surrounding nonperfused tissue. The perfused region in both gray and white matter was hypointense (black) compared with surrounding noninfused tissues. This region perfused with ferumoxtran-10 increased steadily as the Vi increased during the infusions (Fig. 3) .
Effect of Rate. To determine a maximal infusion rate with- out leakback in gray and white matter, 1 mg/ml ferumoxtran-10 was infused into primate gray or white matter at increasing rates. Leakback was determined using real-time T2-weighted coronal MR images in the plane of the infusion cannula. Leakback along the needle track occurred at infusion rates greater than 1.5 l/minute in both gray and white matter (Fig. 4) .
Infusate Distribution Pattern. There was a consistent pattern of distribution demonstrated by real-time MR imaging in each of the infused primates. At the start of the infusions, a cylindrical anulus formed around the distal portion of the infusion cannulae (Fig. 3) . This anulus expanded radially to assume a more spherical distribution pattern with increasing Vi in both gray and white matter. This radial expansion continued with increasing Vi until the rate of infusion was escalated to greater than 1.5 l/minute. At rates greater than 1.5 l/minute (see previous paragraph), leakback around the infusion cannula occurred, resulting in an enlarging cylindrical anulus around the more proximal portion of the infusion cannula (Fig. 4) .
Relationship of Vd to Vi. To determine the relationship of the Vd to the Vi, volumetric analyses of the infused areas at various time points during the infusion were performed. Consistent with the imaging appearance during infusion, the Vd of ferumoxtran-10 increased linearly with the Vi in both gray (R 2 = 0.98) and white (R 2 = 0.98) matter (Fig. 5) . The mean Vd/Vi ratio in the monkeys for gray matter (4.1 Ϯ 0.2; mean Ϯ SEM) was significantly larger (p Ͻ 0.01) than it was in white matter (2.3 Ϯ 0.1).
Homogeneity of Capsid Distribution. To determine the homogeneity of the infusion, cross-sectional line profiles were analyzed over the infused region as determined by quantitative autoradiography. Distribution of capsid was uniform and formed a "square-shaped" distribution pattern, with a sharp gradient drop-off at the edges (Fig. 6 ). There was a 12% variance in concentration across the infusion plateau.
Safety of CED of Ferumoxtran-10
Clinical Observation. To determine the potential for acute or chronic toxicity of infused ferumoxtran-10, the primates underwent serial clinical examinations for up to 72 days (range 0-72 days; Table 1 ). No animal had a detectable neurological deficit at any point after infusion.
Histological Evaluation. Analysis of tissue sections from the infused region stained with Luxol fast blue and H & E revealed normal tissue architecture and no evidence of tissue toxicity. There was evidence of gliosis limited to the region immediately surrounding the cannula track (Fig. 7) .
Discussion
Advantages of CED
Convection-enhanced delivery relies on bulk flow to distribute substances within the interstitial spaces of the CNS. 3 Unlike intraventricular or intrathecal delivery, which rely on diffusion, convection is not limited by an infusate's molecular weight, concentration, or diffusivity. 29 In contrast to bolus injection of infusate into CNS tissue, which generates high infusion pressure that can result in tissue damage, sig-
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Convection of virus-sized particles nificant leakback, and limited tissue distribution, CED is driven by a small hydrostatic pressure that avoids these limitations. 3, 10, 21, 30 Because convective delivery directly distributes molecules within the parenchyma through a cannula, it can be used to target selected regions of the CNS in a manner that bypasses the blood-brain barrier. Previous experiments have shown that the bulk flow properties of convective delivery can be exploited to deliver reliably a variety of small-molecular-weight compounds as well as large proteins in a homogeneous manner. 22, 24, 38 Despite the increasing information available on the convective distribution characteristics of many therapeutic compounds of various molecular sizes, little information exists regarding the precise distribution properties of virus and virus-sized molecules. To determine the convective properties and optimal delivery parameters of virus and virus-sized particles, we examined the distribution of AAV and a similar sized surrogate imaging tracer under varying convective parameters.
Current Study
AAV Vector. Derived from a nonpathogenic virus from the Parvoviridae family, AAV has a simple, nonenveloped icosahedral protein coating with a single strand of DNA. The lack of immunogenicity and no known pathogenicity make AAVs a potentially ideal vector for therapeutic genetic manipulation. Unlike other viruses, which need dividing cells to replicate, AAV can transfect nondividing cells. This virus integrates into chromosome 19 by forming an AAVchromosome complex at the chromosomal integration site.
Although there are several AAV serotypes (1-8) with differing properties, 34 we chose AAV-1 for several reasons. For one, AAV-1 is potent and has broad tropism for cells in the CNS. Also, compared with the AAV-2 serotype that can bind to heparin-sulfate proteoglycans on cell wall within the interstitial space and may require heparin coinfusion to maximize convective distribution, AAV-1 has a relatively inert extracellular space binding profile. 34 Finally, recent advances allow production of high titers of homogeneous AAV-1, which permits a high enough concentration and, subsequently, sufficiently high specific activity of 35 S-AAV for accurate detection and quantification of Vd by quantitative autoradiography. with dextran. 40 Because its mean diameter is 24 nm, it is similar in size to AAV capsids (24 nm). Based on their molecular composition, ferumoxtran-10 molecules are relatively inert with respect to binding to the extracellular matrix. The measured volume on MR imaging is dependent on the concentration of ferumoxtran-10 in the infusate, the particular algorithm used for volume segmentation, and the MR imaging parameters used. 40 Because the measured Vd of ferumoxtran-10 based on MR imaging is dependent on the infused concentration, it was critical to determine a concentration of this imaging agent that would accurately predict the distribution of viral capsids (as determined by quantitative autoradiography). Previously, Kroll et al. 20 infused the rat striatum with increasing concentrations (2.7 to 13.5 mg/ml) of a similar sized dextran-coated iron oxide molecule and found that the Vd on MR imaging increased nonlinearly with increasing concentration. Similar to our data, they found that at concentrations greater than 1 mg/ml the MR imaging-determined Vd was greater than the actual distribution as quantified histologically. By examining serial concentrations (including a lowest concentration of 0.1 mg/ml; Fig. 1 ), we were able to determine that an infused concentration of 1 mg/ml of ferumoxtran-10 most closely predicted the true Vd of the viral capsid (based on quantitative autoradiography). Moreover, as predicted, concentrations lower than 1 mg/ml underestimated the actual Vd of viral capsids.
Real-Time MR Imaging of Ferumoxtran-10. The use of real-time imaging of infused particles in rodents and primates will be critical to the development of human applications to monitor and tailor specific treatment paradigms for various CNS diseases. 36, 37 Use of MR imaging during ferumoxtran-10 infusions revealed a well-defined hypointense region of distribution that was easily distinguishable from surrounding tissue (Fig. 3 ) in white and gray matter. This clear and definable demarcation of infusate from normal tissue permits accurate monitoring, precise volume analysis, and real-time adjustment of infusion parameters if necessary. Moreover, a similar monitoring paradigm for CED will be critical in pathological states because alterations in tissue (for example, in cases involving infiltrative tumor cells, cysts, and/or edema) will likely affect distribution.
Previously, Kordower et al. 17 used CED to distribute a lentivirus vector (80-100 nm) carrying genetic information for the intracellular production of glial cell line-derived neurotrophic factor to the primate striatum. Augmented dopaminergic function in the virus-infused striatum was identified on positron emission tomography testing and correlated with behavioral improvements in a primate parkinsonian model. This same experiment performed in older monkeys showed an amelioration of striatal cell loss on the side treated with glial cell line-derived neurotrophic factor. Despite the imaging, behavioral, and histological improvements in these animals, lack of a surrogate imaging tracer made it impossible to determine the actual distribution and effectiveness of gene transfection. Future investigations in which surrogate tracers with appropriately matched genetic vectors are used in preclinical disease models and in the clinical setting should resolve a variety of issues. These include the following: determining maximal infusion rate; factors affecting leakback (for example, cannula size and design); effectiveness of gene transfection; effect of coinfusion of molecules that may affect transgene expression and/or volume (molecules such as mannitol, heparin, and so on); 26, 28 safety; and the optimal parameters of infusion under various tissue conditions.
The Vd/Vi Ratio. The Vd increased linearly with Vi for both the gray (striatum) and white (R 2 = 0.98) matter. The mean Vd/Vi ratio was significantly higher (p Ͻ 0.01) in gray matter (4.1 Ϯ 0.16; mean Ϯ SEM) than in white matter (2.3 Ϯ 0.1) (Fig. 5) . The Vd and ultimately the Vd/Vi ratio in a given tissue type is determined by a multitude of factors including the total Vi, the extracellular volume fraction (including variability due to poroelastic expansion generated by elevated interstitial pressures), channel blocking, binding or adsorption to cell surfaces or extracellular matrix, and losses due to degradation or microvascular transport processes. In the present experiments, infusion of ferumoxtran-10 at 1 mg/ml in gray matter (and segmentation by the two standard deviations rule for MR imaging) generates a Vd/Vi ratio (4.1 Ϯ 0.16) that is slightly less than those observed previously by using quantitative autoradiography for albumin (66 kD; 8 nm) in rat striatum (5.2 Ϯ 0.5 at 0.5 l/ minute or 4.7 Ϯ 1.0 at 1 l/minute) 7 or for antisense phosphorothioate oligonucleotides in rat striatum (5.2 at 0.3 l/ minute), 5 thus suggesting minimal interaction of ferumoxtran-10 with the extracellular space and a Vd slightly different from that of small or protein-sized molecules. A particle of similar hydrodynamic radius, the AAV-1 capsid, was found by quantitative autoradiography in this study to be characterized by a similar Vd/Vi value of 5.5 Ϯ 0.8 when delivered at 0.1 l/ minute. This is greater than a previously reported value of 3.3 for AAV-2 determined using fluorescence techniques. 6 In our study of ferumoxtran-10 infusion to white matter, a significantly lower Vd/Vi ratio was observed. This value (2.3 Ϯ 0.1) contrasts with a computed tomography-derived Vd/Vi value of 4.1 Ϯ 0.7 reported for iopamidol distribution and the MR imaging-derived value of 4.5 Ϯ 0.4 reported for gadolinium-diethylenetriamine pentaacetic acid distribution in the frontal white matter of nonhuman primates, 9, 32 and indicates that ferumoxtran-10 interacts specifically with white matter to reduce its tissue Vd. The underlying mechanism is uncertain, but several possibilities may be considered. One is that ferumoxtran-10 binds preferentially to components of the white matter, thus retarding its spread. This appears unlikely, however, given that the iron oxide nanoparticles are coated with dextran, and dextran alone has not exhibited binding in white matter. 9 Another possibility is that these particles may seize inside some of the smallest interstitial channels. Initially this would raise the interstitial pressure and, depending on the exact magnitude of this increase, begin to drive carrier fluid across the microvasculature, so tending to reduce the effective infusate volume. However, microvascular fluid loss is not likely to be major, because the capillary-area product for small-molecularweight compounds in white matter has been shown to be only half that for gray matter, 11 and thus is indicative of the tissue's ability to sustain a doubling of pressure before losing fluid at a rate comparable even to that of gray matter. Furthermore, and more importantly, any increase in interstitial pressure is likely to be reversed by the relatively large poroelastic response of the white matter. 1, 2, 8 Channel blockage would initially elevate the interstitial pressure in the local tissue region, but would quickly be followed by deformation and expansion of the extracellular volume, with a consequent reduction of the white matter Vd for a given Vi. Gray matter would not be expected to show the same reduction in Vd because it is less compliant and can sustain elevated pressure with much less deformation. 2 It should be noted that experimental results similar to ours were also reported by Krauze and colleagues, 18 who found that liposomal (100-to 200-nm) infusions in primates yielded a larger Vd in gray than in white matter.
Effect of Rate. To determine a maximal infusion rate without leakback in gray and white matter, 1 mg/ml ferumoxtran-10 was infused into the primate striatum (gray matter) or frontal white matter at increasing rates. Leakback along the cannula track occurred at infusion rates greater than 1.5 l/minute in both gray and white matter (Fig. 4) . This is consistent with the theoretical estimate of the flow rate required in primate gray matter to generate a sufficiently long backflow distance along the 28-gauge cannula to produce a distinct solute distribution above the main infusion volume. From the left side of Fig. 4 , the distance from the cannula tip to the dorsal surface of the infused volume is approximately 6 mm. Using a previously developed formula for the backflow distance in gray matter, 29 this tip-to-dorsal-surface distance is predicted to be just exceeded by use of a 1.5 l/ minute volumetric flow rate (a backflow distance of 6.6 mm is predicted), consistent with leakback just at the limit of observability. Our experimental findings indicate that such a high flow rate can also be supported in the frontal white matter of the primate. In turn, these findings suggest that large structures in the primate or human brain may be dosed at a relatively high flow rate, thus reducing the duration of infusion, without losing treatment agent through leakback to nontargeted regions, including the subarachnoid space. However, structures smaller than the putamen still have to be infused at lower flow rates (between 0.1 and 0.5 l/minute), because they cannot accommodate backflow distances of 6 mm or larger without substantial shunting of infused agent to nontargeted areas beyond the structure's surface.
Infusate Distribution Pattern. Real-time MR imaging permitted precise evaluation of the infusate distribution pattern over a range of Vi and infusion rates. The MR imaging revealed that a cylindrical anulus formed around the distal portion of the infusion cannula at the start of infusion (initial infusion rates of 0.1-0.5 l/minute). This cylindrical anulus then expanded radially to assume a more spherical distribution pattern with increasing Vi in both gray and white matter (Fig. 3) . The radial expansion continued with increasing Vi unless the rate of infusion was escalated to more than 1.5 l/minute, at which point leakback around the more proximal portion of the infusion cannula occurred (Fig. 4) .
Based on mathematical modeling by Morrison et al. 29 for CED, a narrow cylindrical anular manifold should form around the cannula tip at the start of infusion. This model of initial anulus formation predicts that pressure in the anulus diminishes with distance from the cannula tip so that relative partitioning into the surrounding tissues is largely controlled by regional hydraulic conductivity. As seen in these experiments, this anulus should then partition into a more spherical infusion mass in the surrounding tissues, provided that the rate of infusion does not exceed a critical value (1.5 l/minute in this case) determined by tissue and infusate properties.
Homogeneity of Capsid Distribution. The distribution of the capsid was homogeneous, with a variance of 12% across the infusion (Fig. 6) . Analysis of capsid concentration by quantitative autoradiography showed uniformity, with a sharp drop-off at the edges of the infused region ("squareshaped" profile). These findings are consistent with previous studies of CED of low-and high-molecular-weight particles. 3, 7, 22, 23 This supports the ability of this method to distribute molecules of varying sizes in a highly uniform concentration over targeted regions.
Although infusion parameters used in this study provided a homogeneous "square-shaped" distribution pattern, there are potential variables that could affect the homogeneity of interstitial infusate distribution for infusions using convection, particularly of small molecules, and these include rate and Vi. At low infusion rates (Ͻ 0.1 l/minute), diffusion will become the dominant distribution force. Subsequently, the concentration curve in this scenario would lack the plateau portion of the "square-shaped" profile (seen with convection) and a steep drop-off starting from the point of delivery would result. It is also conceivable that if an infusion is continued long enough to reach a steady-state Vd, diffusion at the edges of the perfused area may occur (particularly with small molecules) and alter the shape of the distribution curve at the edges of the perfused regions (sloping of the edges).
Safety of CED of Ferumoxtran-10. The CED of ferumoxtran-10 and viral capsids was well tolerated. There was no clinical or histological evidence of neurological injury in the rat or primate models. None of the animals demonstrated evidence of neurological deficits after infusion at any point during the observation period (Յ 72 days). These findings are consistent with previous studies that have shown that large volumes can be delivered by convection without any deleterious effect.
Although we detected no toxicity in the animals infused in this study, a potential concern is that free iron in the CNS may be detrimental to neurons. Nakamura et al. 33 found that oxidation of free iron particles from the breakdown of intracerebral hemorrhage could lead to neuronal cell damage. Moreover, the accumulation of iron stores in the CNS has been associated with behavioral changes in rats. 15 Despite these findings, preclinical and clinical studies have shown that intravascular or intraparenchymal infusion of iron oxide-based MR imaging contrast agents is safe.
14,31
Conclusions Convection-enhanced delivery can be used to deliver AAV capsids and similar sized particles safely and effectively to the CNS over clinically relevant volumes. Moreover, real-time MR imaging of ferumoxtran-10 during infusion reveals that AAV capsids and similar sized particles have different convective delivery properties than do smaller proteins and other compounds.
